A61K - Cooperative Patent Classification

CPC - A61K - 2013.07 - page 74
A61K 51/0442 . . . . . { having three-membered rings, e.g. aziridine }
A61K 51/0444 . . . . . { having four-membered rings, e.g. azetidine }
A61K 51/0446 . . . . . { having five-membered rings with one nitrogen as the only ring hetero
atom, e.g. sulpiride, succinimide, tolmetin, buflomedil }
A61K 51/0448 . . . . . . { tropane or nortropane groups, e.g. cocaine }
A61K 51/0451 . . . . . . { having four such rings, e.g. phorphine derivatives, bilirubin,
biliverdine ( hemin, hematin A61K 51/0472 ) }
NOTE
-
Porphyrins or texaphyrins used as complex-forming compounds,
i.e. wherein the nitrogen atoms forming the central ring system
complex the radioactive metal, are classified in A61K 51/0485
A61K 51/0453 . . . . . { having five-membered rings with two or more ring hetero atoms, at least
one of which being nitrogen, e.g. tetrazole }
A61K 51/0455 . . . . . { having six-membered rings with one nitrogen as the only ring hetero
atom }
A61K 51/0457 . . . . . . { Vesamicol }
A61K 51/0459 . . . . . { having six-membered rings with two nitrogen atoms as the only ring
hetero atoms, e.g. piperazine }
A61K 51/0461 . . . . . { having six-membered rings with three nitrogens as the only ring hetero
atoms, e.g. chlorazanil, melamine ( melarsoprol A61K 51/0472 ) }
A61K 51/0463 . . . . . { having six-membered rings with at least one nitrogen and one oxygen
as the ring hetero atoms, e.g. 1,2-oxazines }
A61K 51/0465 . . . . . { having six-membered rings with at least one nitrogen and one sulfur as
the ring hetero atoms, e.g. sulthiame }
A61K 51/0468 . . . . . { having seven-membered rings, e.g. azelastine, pentylenetetrazole }
A61K 51/047 . . . . . . { Benzodiazepines }
A61K 51/0472 . . . . { containing heavy metals, e.g. hemin, hematin, melarsoprol }
A61K 51/0474 . . . { complexes or complex-forming compounds, i.e. wherein a radioactive metal (
e.g. 111In3+ ) is complexed or chelated by e.g. a N2S2, N3S, NS3, N4
chelating group }
NOTE
-
Classification is made according to the nature of this complex-forming
agent, if it is either an uncommon or new complexing agent (not the usual
DTPA, DOTA, DOTP, MAG3 etc...groups) that forms the real contribution
to the claimed invention (radioimaging or radiotherapeutic agent), or if it is
not conjugated to any further molecule, e.g. which is not conjugated to a
polymer, peptide, protein or antibody. In that latter case, the radioactive
agent is e.g. a radioactive metal chelate
A61K 51/0476 . . . . { complexes from monodendate ligands, e.g. sestamibi }
A61K 51/0478 . . . . { complexes from non-cyclic ligands, e.g. EDTA, MAG3 }
A61K 51/048 . . . . . { DTPA ( diethylenetriamine tetraacetic acid ) }
A61K 51/0482 . . . . { chelates from cyclic ligands, e.g. DOTA }
A61K 51/0485 . . . . { Porphyrins, texaphyrins wherein the nitrogen atoms forming the central ring
system complex the radioactive metal }